QuidelOrtho Corporation (QDEL)

From the record

QuidelOrtho Corporation's filings since 2022 show 1 warning event: an auditor change (8-K item 4.01, the latest 2025-03-04) (its current reports).

From the record

QuidelOrtho Corporation's 6 filed years say what it did: revenue went from $1.7 billion in fiscal 2021 to $2.7 billion in fiscal 2025, up 10.5% a year; it rose in 2 of 5 years; the deepest fall was 16% from fiscal 2023 to fiscal 2025; net income was positive in 3 of 6 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-28, QuidelOrtho Corporation's diluted share count grew about 5.7% a year, and dividends and buybacks returned about 2% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 1 sale and 9 purchases of their own stock on the open market in the year to 2026-10-19, buying about $1 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-28, QuidelOrtho Corporation lost about 59 cents for every dollar of shareholders' money. Leverage: it owed about 67 cents per dollar of assets, and net share issuance: its share count grew 0.9% over the year (the filed statements).

From the record

QuidelOrtho Corporation's standing among 17 graded names in its industry family: revenue of $2.7 billion in fiscal 2025 ranks in the top 9% by size; a net margin of -41.5% ranks in the top 32%; revenue growth of -5.8% a year over the last 3 filed years ranks in the bottom 34% (its annual reports).

From the record

QuidelOrtho Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Blaser, Brian J. (President and CEO, as filed), filing under that title since 2024-05-16, 2.5 years (bottom 46% of its family); most of the 19 officers and directors filing now have filed since the record of its people begins (2022-06-01), a floor of 4.5 years the record cannot see past, so that part is not read; 15 officer or director changes were reported on Form 8-K since 2023-11-13, against the 19 people in charge now (bottom 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

QuidelOrtho Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $170 million against debt of $2.5 billion leaves -39.9% of its assets as net cash, bottom 8% of its family; cash from operations less capital spending is -3% of revenue (top 34%); research spending of 6.8% of revenue (bottom 28%) (its annual report).

From the record

QuidelOrtho Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew -5.8% a year over the last three filed years against 10.5% over all 6, slowing (bottom 3% of its family); the newest year grew -1.9% (bottom 38%); research spending grew -0.3% a year (top 44%); capital spending grew 10.2% a year (top 23%) (its annual reports). QuidelOrtho Corporation reported 5 lines of business in fiscal 2025: North America at $1.5 billion, EMEA at $361 million, China at $335 million, and 2 more. 4 of 5 grew in the latest filed year, and the largest line is 55% of revenue (its annual report).

From the record

QuidelOrtho Corporation's newest year against its own record: revenue of $2.7 billion in fiscal 2025 came in 6.3% above the $2.6 billion its prior three years' pace pointed to (top 37% of its family); net income of $1.1 billion against a prior three-year average of $504 million (bottom 3%); a net margin of -41.5% against -19.1% before (bottom 16%) (its annual reports).